HIV

Researchers determine why HIV persists in some patients and remains dormant in others.

Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) is approved for treatment of HIV-1 infection.

Pharmacy testing could reduce the number of undiagnosed HIV patients and new infections.

HIV patients not on recommended regimens are less likely to achieve viral suppression and more likely to report side effects.

Did you know that the 14% of undiagnosed HIV patients cause 33% of new infections?

Ebola and AIDS spread rapidly in areas with poor health care systems.

The FDA is considering expanding the use for a drug currently indicated as a chronic hepatitis C (HCV) treatment.

Health information sharing web site helps connect patients among more than 2500 conditions.

Vaginal rings show promise for administering medication and preventing the spread of sexual transmitted infections.

HDACi shows promise as a latency reversal component to purge HIV reservoirs.

Viral induction greater than any other latency reversing agent.

New guidelines based on overwhelming clinical evidence that ART is effective.

More children than previously thought have trouble sleeping, and a third of them are given medication for it.

Prevalence higher among those who used illicit drugs.

Broadly neutralizing antibodies may help defend the body against HIV.

Pharmacist intervention greatly improves treatment adherence.

The treatment mantra for human immunodeficiency virus (HIV) is almost-perfect lifelong adherence to antiretroviral therapy (ART).

Experimental drug blocks key sites on the virus surface that attach and invade human immune cells.

Self-testing may help control global spread of HIV/AIDS.

Researchers examine how immunodeficiency diseases avoid immune system attacks.

Current HIV treatment guidelines are based on data obtained primarily from men.

Just one follow-up phone call can keep asymptomatic adolescents with sexually transmitted infections (STI) adherent to treatment.

Hepatitis C incidence rate among HIV-positive men who have sex with men grew three-fold from 1991 to 2010.

Initial price hike justified through claims the profits could fund research and development.

Medications enable the management of HIV.